-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
How Many Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares Do Institutions Own?
How Many Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares Do Institutions Own?
The big shareholder groups in Shandong Xinhua Pharmaceutical Company Limited (HKG:719) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. We also tend to see lower insider ownership in companies that were previously publicly owned.
With a market capitalization of HK$11b, Shandong Xinhua Pharmaceutical is a decent size, so it is probably on the radar of institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Shandong Xinhua Pharmaceutical.
See our latest analysis for Shandong Xinhua Pharmaceutical
SEHK:719 Ownership Breakdown August 4th 2022What Does The Institutional Ownership Tell Us About Shandong Xinhua Pharmaceutical?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
As you can see, institutional investors have a fair amount of stake in Shandong Xinhua Pharmaceutical. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Shandong Xinhua Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.
SEHK:719 Earnings and Revenue Growth August 4th 2022Shandong Xinhua Pharmaceutical is not owned by hedge funds. Our data shows that Hualu Holdings Co.,ltd. is the largest shareholder with 37% of shares outstanding. Hong Kong Exchanges and Clearing Limited is the second largest shareholder owning 29% of common stock, and Shanghai Chitai Asset Management Co., Ltd. holds about 4.1% of the company stock.
To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
Insider Ownership Of Shandong Xinhua Pharmaceutical
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
We can see that insiders own shares in Shandong Xinhua Pharmaceutical Company Limited. The insiders have a meaningful stake worth HK$127m. Most would see this as a real positive. It is good to see this level of investment by insiders. You can check here to see if those insiders have been buying recently.
General Public Ownership
The general public, who are usually individual investors, hold a 24% stake in Shandong Xinhua Pharmaceutical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Company Ownership
We can see that Private Companies own 37%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Public Company Ownership
We can see that public companies hold 29% of the Shandong Xinhua Pharmaceutical shares on issue. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Shandong Xinhua Pharmaceutical better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Shandong Xinhua Pharmaceutical , and understanding them should be part of your investment process.
Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
山东新华药业股份有限公司(HKG:719)的大股东集团对该公司拥有控制权。一般来说,随着公司的成长,机构会增加他们的持股。相反,随着时间的推移,内部人士往往会减少他们的持股。我们还倾向于看到,以前为公众所有的公司的内部人持股比例较低。
山东新华医药的市值为110亿港元,规模相当可观,因此很可能在机构投资者的雷达上。我们对该公司所有权的分析显示,机构投资者买入了该公司的股票。让我们仔细看看不同类型的股东能告诉我们关于山东新华药业的什么。
查看我们对山东新华药业的最新分析
联交所:719所有权分类2022年8月4日关于山东新华药业,机构持股告诉了我们什么?
许多机构以一个接近当地市场的指数来衡量它们的表现。因此,他们通常更关注那些被纳入主要指数的公司。
如你所见,机构投资者在山东新华药业持有相当数量的股份。这表明在专业投资者中有一定的可信度。但我们不能仅仅依靠这一事实,因为机构有时会做出糟糕的投资,就像每个人一样。当多家机构持有一只股票时,它们总是面临“拥挤交易”的风险。当这样的交易出错时,多方可能会竞相快速抛售股票。在一家没有增长历史的公司,这一风险更高。你可以在下面看到山东新华医药的历史收益和营收,但请记住,故事中总是有更多的内容。
联交所:719盈利及收入增长2022年8月4日山东新华药业并非由对冲基金所有。我们的数据显示,华录控股有限公司。是最大的股东,拥有37%的流通股。香港交易所有限公司是第二大股东,持有29%的普通股,上海奇泰资产管理有限公司持有公司约4.1%的股份。
为了让我们的研究更有趣,我们发现,前两名股东拥有公司的多数股权,这意味着他们足够强大,可以影响公司的决策。
虽然研究一家公司的机构持股可以增加你的研究价值,但研究分析师的建议以更深入地了解一只股票的预期表现也是一个很好的做法。据我们所知,没有分析师对该公司的报道,所以它很可能在雷达下飞行。
山东新华医药的内部人所有权
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层对董事会负责,董事会应代表股东的利益。值得注意的是,有时最高层管理人员本身也是董事会成员。
大多数人认为内部人持股是积极的,因为它可以表明董事会与其他股东很好地结盟。然而,在某些情况下,太多的权力集中在这个群体中。
我们可以看到,内部人士持有山东新华药业有限公司的股份。这些内部人士持有价值1.27亿港元的可观股份。大多数人会认为这是一个真正的积极因素。看到内部人士的投资达到这样的水平是件好事。你可以在这里查看这些内部人士最近是否一直在买入。
一般公有制
一般公众通常是个人投资者,他们持有山东新华医药24%的股份。虽然这群人不一定能发号施令,但它肯定能对公司的运营方式产生真正的影响。
私营公司所有权
我们可以看到,私营公司拥有37%的已发行股份。或许有必要对此进行更深入的研究。如果关联方,如内部人士,对这些私营公司中的一家有利害关系,则应在年报中披露。私营公司也可能对该公司拥有战略利益。
上市公司所有权
我们可以看到,上市公司持有山东新华医药29%的已发行股份。我们不能确定,但很有可能这是一个战略利益攸关方。这些业务可能是相似的,也可能是合作的。
接下来的步骤:
拥有一家公司股票的不同集团总是值得考虑的。但要更好地了解山东新华药业,我们还需要考虑许多其他因素。例如,考虑一下无处不在的投资风险幽灵。我们已经确定了三个警告信号与山东新华药业合作,了解他们应该是你投资过程的一部分。
当然了这可能不是最值得购买的股票。。所以让我们来看看这个免费 免费有趣的公司名单。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧